Royalty Pharma plc (NASDAQ:RPRX) Position Trimmed by Tredje AP fonden

Tredje AP fonden decreased its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 50.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 51,175 shares of the biopharmaceutical company’s stock after selling 51,175 shares during the period. Tredje AP fonden’s holdings in Royalty Pharma were worth $1,305,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Rakuten Securities Inc. increased its stake in Royalty Pharma by 160.5% during the fourth quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 1,003 shares during the last quarter. Jupiter Asset Management Ltd. bought a new position in shares of Royalty Pharma during the fourth quarter worth about $4,950,000. EverSource Wealth Advisors LLC grew its position in shares of Royalty Pharma by 24.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 4,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 818 shares during the last quarter. AGF Management Ltd. bought a new position in shares of Royalty Pharma during the fourth quarter worth about $2,513,000. Finally, Wealthfront Advisers LLC grew its position in shares of Royalty Pharma by 1,655.6% during the fourth quarter. Wealthfront Advisers LLC now owns 188,935 shares of the biopharmaceutical company’s stock worth $4,820,000 after acquiring an additional 178,173 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

RPRX stock opened at $32.77 on Friday. The company has a market capitalization of $18.89 billion, a P/E ratio of 22.60, a PEG ratio of 2.31 and a beta of 0.47. The company has a 50-day simple moving average of $31.58 and a 200 day simple moving average of $28.56. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Sell-side analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were issued a $0.22 dividend. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.69%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio is presently 60.69%.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.